Publication List


At PharmIdeas, we pride ourselves on the diversity and the complexity of the publications we have produced over our 25+ years of existence. Our publications can be geared towards the needs of our clients (such as internal documents) or can be targeted to a specialized public such as decision-makers or conference attendees.

Feel free to type in any keyword of interest (e.g., Psychiatry) in the search box above the table for a more specific filtering process.


Entries  

Year Authors Title Journal/Meeting Volume Issue Pages Therapeutic Area / Topic Medium
2020 Iskedjian M, De Vol E, Elshanawy M, Bazarbashi S. Elicitation of Health Utilities in Oncology in the Kingdom of Saudi Arabia JCO Global Oncology 2020 In Press Online Oncology, Health Technology Assessment, Helth Utilities Peer-Reviewed Journal Article
2020 Bazarbashi S, De Vol EB, Maraiki F, Al-Jedai A, Ali AA, Aljuffali IA, Iskedjian M. Empirical Monetary Valuation of a Quality-Adjusted Life-Year in the Kingdom of Saudi Arabia: A Willingness-to-Pay Analysis Pharmacoeconomics - Open 2020 2020-04-14 Online WTP, Quality-Adjusted Life-Year, QALY Valuation, Reimbursement Peer-Reviewed Journal Article
2014 Iskedjian M, Desjardins B, Walker JH Comparing Public Influenza Immunization Programmes In Ontario And Québec, Canada Value in Health 17 3 A152-153 Immunisation, Public Health Abstract
2013 Benjamin L, Buthion V, Iskedjian M, Farah B, Rioufol C, Vidal-Trécan G. Budget impact analysis of the use of oral and intravenous anti-cancer drugs for the treatment of HER2-positive metastatic breast cancer. Journal of Medical Economics 16 1 96-207 Oncology, Breast cancer, Budget Impact Analysis Peer-Reviewed Journal Article
2012 Iskedjian M, Tinmouth A, Arnold DM, Deuson R, Isitt J, Mikhael J. Elicitation of utility scores in Canada for immune thrombocytopenia treated with romiplostim or watch and rescue. Journal of Medical Economics 15 2 313-331 Thrombocytopenia, Hematology, Health Utilities Peer-Reviewed Journal Article
2012 Iskedjian M, Navarro V, Farah B, Berbari J, Lelorier J. Examination of Preference Elicited From the General Public: Comparisons of Results From the Time Trade-Off and Standard Gamble ISPOR, 15th Annual European Congress, Berlin, Germany, November 2012. NA NA NA Time Trade-Off, Standard Gamble, Methodology Conference Presentations and Lectures
2012 Iskedjian M, Navarro V, Farah B, Berbari J, Lelorier J. Examination of Patient Preference: Comparisons of Results From the Time Trade-Off and Standard Gamble ISPOR, 15th Annual European Congress, Berlin, Germany, November 2012. NA NA NA Time Trade-Off, Standard Gamble, Patient reported outcomes, Methodology Conference Presentations and Lectures
2012 Iskedjian M, Gafni A, McLean A, White J, Provencher S, Farah B, Berbari J, Watson JA. Preference and Willingness to Pay for a Treatment of Pulmonary Arterial Hypertension ISPOR, 15th Annual European Congress, Berlin, Germany, November 2012. NA NA NA Pulmonary Arterial Hypertension Conference Presentations and Lectures
2012 Reed SD, Ramsey R, Iskedjian M, O'Donnell J. The nuts and bolts of presenting evidence to health authorities. 17th ISPOR Annual International Meeting, Washington, DC, June 2012. NA NA NA Reimbursement, Real World Evidence Conference Presentations and Lectures
2012 Su J, Prescott S, Sinn J, Tang M, Smith P, Heine RG, Spieldenner J, Iskedjian M Cost-effectiveness of partially-hydrolyzed formula for prevention of atopic dermatitis in Australia. Journal of Medical Economics 15 6 1064-77 Dermatology, Nutrition Peer-Reviewed Journal Article
2012 Iskedjian M, Haschke F, Farah B, van Odijk J, Berbari J, Spieldenner J. Economic evaluation of a 100% whey-based partially hydrolyzed infant formula in the prevention of atopic dermatitis among Danish children. Journal of Medical Economics 15 2 394-408 Dermatology, Nutrition Peer-Reviewed Journal Article
2012 Iskedjian M, Belli D, Farah B, Navarro V, Detzel P. Economic evaluation of a 100% whey-based partially hydrolyzed infant formula in the prevention of atopic dermatitis among Swiss children. Journal of Medical Economics 15 2 378-393 Dermatology, Nutrition Peer-Reviewed Journal Article
2012 Iskedjian M, Tinmouth AT, Arnold DM, Deuson R, Isitt JJ, Mikhael J. Elicitation of utility scores in Canada for immune thrombocytopenia treated with romiplostim or watch and rescue. Journal of Medical Economics 15 2 313-331 Immune thrombocytopenia, Hematology Peer-Reviewed Journal Article
2011 Spieldenner J, Belli D, Dupont C, Haschke F, Iskedjian M, Nevot Falcó S, Szajewska H, von Berg A. Partially hydrolysed 100% whey-based infant formula and the prevention of atopic dermatitis: comparative pharmacoeconomic analyses. Annals of Nutrition and Metabolism 59 Suppl 1 44-52 Dermatology, Nutrition Peer-Reviewed Journal Article
2011 Iskedjian M, Jaszewski B, Desjardins O. Comparison of scores derived from the use of the BS-11 Scale and the pain attribute of the HUI-3. The Patient: Patient-Cente#2461aa Outcomes Research 4 4 259-65 Patient-Reported Outcomes, Quality of life, Mapping Peer-Reviewed Journal Article
2011 Iskedjian M, Covert D, Walker J. Persistence with prostaglandin agonist use with and without adjunctive therapy for glaucoma patients - A Canadian population-based analysis. The Patient: Patient-Cente#2461aa Outcomes Research 4 2 1-9 Glaucoma, Ophthalmology, Prostaglandin Therapeutics Peer-Reviewed Journal Article
2011 Berbari J, Reynolds S, Heil-Ruess M, Iskedjian M. Systematic review of the epidemiologic literature on atopic dermatitis in children. ISPOR 16th Annual International Meeting, Baltimore, MD, USA, May 21-25, 2011 NA NA NA Dermatology, Nutrition Conference Presentations and Lectures
2011 Iskedjian M, Navarro V, Khondoker F, Farah B. Systematic review of the quality of life literature in children with atopic dermatitis. ISPOR 16th Annual International Meeting, Baltimore, MD, USA, May 21-25, 2011 NA NA NA Dermatology, Nutrition Conference Presentations and Lectures
2011 Iskedjian M, Navarro V, Khondoker F, Farah B. Systematic review of the economic literature on atopic dermatitis in children. ISPOR 16th Annual International Meeting, Baltimore, MD, USA, May 21-25, 2011 NA NA NA Dermatology, Nutrition Conference Presentations and Lectures
2011 Iskedjian M, von Berg A, Bauer C-P, Hoeger P, Farah B, Possner M, Spieldenner J. Economic evaluation of a 100% whey-based partially hydrolyzed formula for the prevention of atopic dermatitis among German children: Preliminary results. 44th Annual Meeting of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition, Sorrento, Italy, May 25-28, 2011 NA NA NA Dermatology, Nutrition Conference Presentations and Lectures
2010 Iskedjian M, Dupont C, Spieldenner J, Kanny G, Raynaud F, Farah B, Haschke F. Economic evaluation of a 100% whey-based partially hydrolyzed formula in the prevention of atopic dermatitis among French children. Current Medical Research and Opinion 26 11 2607-2626 Dermatology, Nutrition Peer-Reviewed Journal Article
2010 Iskedjian M, Szajewska H, Spieldenner J, Farah B, Berbari J. Meta-analysis of a partially hydrolyzed 100%-whey infant formula vs. extensively hydrolyzed infant formulas in the prevention of atopic dermatitis. Current Medical Research and Opinion 26 11 2599-2606 Dermatology, Nutrition Peer-Reviewed Journal Article
2010 Iskedjian M, De Serres G, Einarson T, Walker J. Economic impact of the introduction of an accellular pertussis vaccine in Canada: a 6-year analysis. Vaccine 28 3 714-723 Infectious Diseases Peer-Reviewed Journal Article
2010 Iskedjian M, Iyer S, Librach SL, Wang M, Farah B, Berbari J. Methylnaltrexone in the treatment of opioid induced constipation in cancer patients receiving palliative care - Willingness-to-pay and cost-benefit analysis. Journal of Pain and Symptom Management 41 1 104-115 Geriatrics, Oncology, Gastoenterology Peer-Reviewed Journal Article
2010 Iskedjian M, Navot Falco S, Spieldenner J, Casas Ramisa R, Claver Monzon A, Gonzalez Enseñat MA, Farah B, Berbari J. Evaluation of a 100% whey-based partially hydrolyzed formula in the prevention of atopic dermatitis among Spanish children. Value in Health 13 7 A400 Dermatology, Nutrition Abstract
2010 Iskedjian M, Spieldenner J, Jarvi A, Farah B, Navarro V. Evaluation of a 100% whey-based partially hydrolyzed formula in the prevention of atopic dermatitis among Danish children: Preliminary analyses. Value in Health 13 7 A400 Dermatology, Nutrition Abstract
2010 Iskedjian M, Dupont C, Spieldenner J, Kanny G, Raynaud F, Farah B, Haschke F. Evaluation of a 100% whey-based partially hydrolyzed formula in the prevention of atopic dermatitis among French children. Value in Health 13 7 A400 Dermatology, Nutrition Abstract
2010 Iskedjian M, Navot Falco S, Spieldenner J, Casas Ramisa R, Claver Monzon A, Gonzalez Enseñat MA, Farah B, Berbari J. Clinical and economic impact of a partially hydrolyzed formula in the prevention of atopic dermatitis in Spanish children. Pediatric Research Suppl-1 NA 358-359 Dermatology, Nutrition Abstract
2010 Iskedjian M, Dupont C, Spieldenner J, Kanny G, Raynaud F, Farah B, Berbari J, Haschke F. Clinical and economic impact of a partially hydrolyzed formula in the prevention of atopic dermatitis in French children. Pediatric Research Suppl-1 NA 358 Dermatology, Nutrition Abstract
2010 Iskedjian M, Szajewska H, Spieldenner J, Farah B, Berbari J, Navarro V. Meta-analysis of a partially hydrolyzed 100%-whey infant formula vs. extensively hydrolyzed infant formulas in the prevention of atopic dermatitis. Value in Health 13 7 A397 Dermatology, Nutrition Abstract
2010 Iskedjian M, Navot Falco S, Spieldenner J, Casas Ramisa R, Claver Monzon A, Gonzalez Enseñat MA, Farah B, Berbari J. Clinical and economic impact of a partially hydrolyzed formula in the prevention of atopic dermatitis in Spanish children. 3rd Congress of the European Academy of Paediatric Societies, Copenhagen, Denmark, October 23-26, 2010 NA NA NA Dermatology, Nutrition Conference Presentations and Lectures
2010 Iskedjian M, Dupont C, Spieldenner J, Kanny G, Raynaud F, Farah B, Berbari J, Haschke F. Clinical and economic impact of a partially hydrolyzed formula in the prevention of atopic dermatitis in French children. 3rd Congress of the European Academy of Paediatric Societies, Copenhagen, Denmark, October 23-26, 2010 NA NA NA Dermatology, Nutrition Conference Presentations and Lectures
2010 Iskedjian M, Navot Falco S, Spieldenner J, Casas Ramisa R, Claver Monzon A, Gonzalez Enseñat MA, Farah B, Berbari J. Evaluation of a 100% whey-based partially hydrolyzed formula in the prevention of atopic dermatitis among Spanish children. ISPOR 13th Annual European Congress, Prague, Czech Republic, November 6-9, 2010 NA NA NA Dermatology, Nutrition Conference Presentations and Lectures
2010 Iskedjian M. Enregistrement & remboursement : Pharmaco-économie réglementaire. LyonBiopole, Lyon, France, March 5, 2010 NA NA NA Pharmacoeconomic Methods Conference Presentations and Lectures
2010 Iskedjian M, Spieldenner J, Jarvi A, Farah B, Navarro V. Evaluation of a 100% whey-based partially hydrolyzed formula in the prevention of atopic dermatitis among Danish children: Preliminary analyses. ISPOR 13th Annual European Congress, Prague, Czech Republic, November 6-9, 2010 NA NA NA Dermatology, Nutrition Conference Presentations and Lectures
2010 Iskedjian M, Dupont C, Spieldenner J, Kanny G, Raynaud F, Farah B, Haschke F. Evaluation of a 100% whey-based partially hydrolyzed formula in the prevention of atopic dermatitis among French children. ISPOR 13th Annual European Congress, Prague, Czech Republic, November 6-9, 2010 NA NA NA Dermatology, Nutrition Conference Presentations and Lectures
2010 Iskedjian M, Szajewska H, Spieldenner J, Farah B, Berbari J, Navarro V. Meta-analysis of a partially hydrolyzed 100%-whey infant formula vs. extensively hydrolyzed infant formulas in the prevention of atopic dermatitis. ISPOR 13th Annual European Congress, Prague, Czech Republic, November 6-9, 2010 NA NA NA Dermatology, Nutrition Conference Presentations and Lectures
2009 Bonafont X, Bock A, Carter D, Brunkhorst R, Carrera F, Iskedjian M, Molemans B, Dehmel B, Robbins S. A meta-analysis of the relative dose of erythropoiesis-stimulating agents in patients undergoing dialysis. Nephrology Dialysis Transplantation Plus (NDT Plus) 2 5 347-353 Nephrology Peer-Reviewed Journal Article
2009 Iskedjian M, Walker JH, Desjardins O, Robin AL, Covert DW, Bergamini MVW, Einarson TR. Effect of selected antihypertensives, antidiabetics, statins and diuretics on adjunctive medical treatment of glaucoma: A population based study. Current Medical Research and Opinion 25 8 1879-1888 Ophthalmology Peer-Reviewed Journal Article
2009 Iskedjian M, Desjardins O, Piwko C, Bereza B, Jaszewski B, Einarson TR. Willingness to pay for a treatment for pain in multiple sclerosis. PharmacoEconomics 27 2 149-158 CNS/Neurology Peer-Reviewed Journal Article
2009 Iskedjian M, Einarson TR, Walker JH, Jovey R, Moulin D. Anticonvulsants, serotonin-norepinephrine reuptake inhibitors, and tricyclic antidepressants in the management of neuropathic pain : A meta-analysis and economic evaluation. Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa, ON NA 116 NA CNS/Neurology Peer-Reviewed Report
2009 Iskedjian M, Einarson TR, Walker JH, Jovey R, Moulin D. Overview of anticonvulsants, serotonin-norepinephrine reuptake inhibitors, and tricyclic antidepressants in the management of neuropathic pain. Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa, ON NA 49 NA CNS/Neurology Peer-Reviewed Report
2009 Arnold DM, Tinmouth A, Iskedjian M, Gafni A, Deuson R, Isitt J, Mikhael J. NA NA NA NA NA NA NA
2009 Arnold DM, Tinmouth A, Iskedjian M, Gafni A, Deuson R, Isitt J, Mikhael J. Eliciting health state utilities for immune (idiopathic) thrombocytopenic purpura: Results of a general public based time trade-off survey. Value in Health 12 7 A382 Hematology Abstract
2009 Desjardins B, Berbari J, Farah B, Azzabi-Zouraq I, Iskedjian M. Health care resources and costs of fibromyalgia: A review of the evidence. Value in Health 12 7 A438 CNS/Neurology Abstract
2009 Iskedjian M, Shapiro M, Wang M, Farah B, Walker J. Health related quality of life and utility scores in menopausal women. Value in Health 12 7 A295 Women's Health Abstract
2009 Iskedjian M, Shapiro M, Wang M, Farah B, Walker J. Prevalence and burden of illness of menopause: A Canadian observational study. Value in Health 12 7 A291 Women's Health Abstract
2009 Iskedjian M. A Canadian based pharmacoeconomic analysis of selected anticonvulsants, SNRIS and TCAS in treating neuropathic pain. Value in Health 12 3 A132 CNS/Neurology Abstract
2009 Arnold DM, Tinmouth A, Iskedjian M, Gafni A, Deuson R, Isitt J, Mikhael J. Eliciting health state utilities for immune (idiopathic) thrombocytopenic purpura: Results of a general public based time trade-off survey. ISPOR 12th Annual European Congress, Paris, France, October 24-27, 2009 NA NA NA Hematology Conference Presentations and Lectures
2009 Desjardins B, Berbari J, Farah B, Azzabi-Zouraq I, Iskedjian M. Health care resources and costs of fibromyalgia: A review of the evidence. ISPOR 12th Annual European Congress, Paris, France, October 24-27, 2009 NA NA NA CNS/Neurology Conference Presentations and Lectures
2009 Iskedjian M, Shapiro M, Wang M, Farah B, Walker J. Health related quality of life and utility scores in menopausal women. ISPOR 12th Annual European Congress, Paris, France, October 24-27, 2009 NA NA NA Women's Health Conference Presentations and Lectures
2009 Iskedjian M, Shapiro M, Wang M, Farah B, Walker J. Prevalence and burden of illness of menopause: A Canadian observational study. ISPOR 12th Annual European Congress, Paris, France, October 24-27, 2009 NA NA NA Women's Health Conference Presentations and Lectures
2009 Iskedjian M. Pharmacoeconomic evaluation: A tool in medical decision making. College of Health Sciences, American University of Armenia, Yerevan, Armenia, July 9, 2009 NA NA NA Pharmacoeconomic Methods Conference Presentations and Lectures
2009 Iskedjian M. Etude non interventionnelle : Faut-il réglementer? Roche & Associés, Lyon, France, June 26, 2009 NA NA NA Pharmacoeconomic Methods Conference Presentations and Lectures
2009 Iskedjian M. A Canadian based pharmacoeconomic analysis of selected anticonvulsants, SNRIS and TCAS in treating neuropathic pain. ISPOR 14th Annual International Meeting, Orlando, FL, USA, May 2009 NA NA NA CNS/Neurology Conference Presentations and Lectures
2008 Iskedjian M, Walker JH, Desjardins O, Covert D, Einarson TR. Cost comparison of prostaglandin analogues: A Canadian population-based analysis. Journal of Medical Economics 11 2 299-310 Prostaglandin Therapeutics Peer-Reviewed Journal Article
2008 Iskedjian M, Walker JH, Bereza B, Einarson TR. Cost-effectiveness of escitalopram in generalized anxiety disorder in Canada. Current Medical Research and Opinion 24 5 1539-1548 CNS/Psychiatry Peer-Reviewed Journal Article
2008 Van Dulmen S, Sluijs E, Van Dijk L, De Ridder D, Heerdink R, Bensing J, Barbui C, Bender B, Byrne N, Connor J, Devine E, Giuffrida A, Haskard K, DiMatteo R, Haynes B, Iskedjian M, Merinder L, Roter D, Schroeder K, Takiya L, Van,Dam H, Van Der Wal M, Van,Eijken M, Vergouwen T, Vermeire E, Wild M, Yildiz A. Furthering patient adherence: A position paper of the international expert forum on patient adherence based on an internet forum discussion. BMC Health Services Research 8 NA 47 Adherence Peer-Reviewed Journal Article
2008 Iskedjian M, Desjardins O, Einarson TR. Development and use of decision boards for determination of the general public’s preference in willingness to pay analysis. Proceedings of the ISPOR 13th Annual International Meeting, Toronto, ON, Canada, May 2008 NA NA NA Pharmacoeconomic Methods Abstract
2008 Bonafont X, Iskedjian M, Machado M, Aziziyeh R, Einarson T, Robbins S, Molemans B, Dehmel B. Dose efficiency observed with darbepoetin alfa in renal patients previously treated with epoetin: A meta-analysis. Pharmacy World & Science 30 5 731 Nephrology, hematopoeisis Abstract
2008 Iskedjian M, Walker JH, De Serres G, Einarson TR. Economic and clinical impact of implementation of an acellular pertussis vaccine in Canada. Value in Health 11 6 A436 Infectious Diseases Abstract
2008 Einarson TR, Walker JH, Machado M, Iskedjian M. Meta-analysis of selected anitconvulsants, SNRIs and TCAs in treating neuropathic pain. Value in Health 11 3 A152 CNS/Psychiatry Abstract
2008 Wang M, Iyer S, Desjardins O, Iskedjian M, Einarson TR. Treatment preference and willingness to pay (WTP) for methylnaltrexone, a novel peripheral opioid antagonist for opioid induced constipation. ISPOR 11th Annual European Congress, Athens, Greece, November 8-11, 2008 11 6 A488-A489 Gasteroenterology Abstract
2008 Iskedjian M, Walker JH, Desjardins O, Covert D, Einarson TR. Prostaglandin agonist use with and without adjunctive therapy for the treatment of glaucoma: A Canadian population based analysis. Value in Health 9 6 A371 Ophthalmology, Prostaglandin Therapeutics Abstract
2008 Iskedjian M, Walker JH, Einarson TR, Desjardins O, Herings RMC, Sukel MPP, Covert D. Prostaglandin agonist use with and without adjunctive therapy for the treatment of glaucoma: A Netherlands population based analysis. Value in Health 11 3 A298 Ophthalmology, Prostaglandin Therapeutics Abstract
2008 Hayward A, Roggenbach M, Purdy C, Caruana D, Einarson TR, Iskedjian M. The development of a standardized clinical algorithmic p#2461aaictor of weight loss after bariatric surgery: Database analysis enables empirical and statistical p#2461aaiction of threshold weight loss by end of third post-operative physician visit. Value in Health 11 3 A152 Obesity Abstract
2008 Purdy CH, Hayward A, Magar RS, Iskedjian M. Incremental savings associated with a decrease in antidepressant medications following bariatric surgery in western New York. Value in Health 11 6 A648 Obesity, CNS/Psychiatry Abstract
2008 Iskedjian M, Desjardins O, Einarson TR. Development and use of decision boards for determination of the general public’s preference in willingness to pay analysis. ISPOR 13th Annual International Meeting, Toronto, ON, Canada, May 2008 NA NA NA Pharmacoeconomic Methods Conference Presentations and Lectures
2008 Bonafont X, Iskedjian M, Machado M, Aziziyeh R, Einarson T, Robbins S, Molemans B, Dehmel B. Dose efficiency observed with darbepoetin alfa in renal patients previously treated with epoetin: A meta-analysis. ESCP 36th European Symposium on Clinical Pharmacy ‘Implementing Clinical Pharmacy in Community and Hospital Settings: Sharing the Experience’, Istanbul, Turkey 25–27 October 2007 NA NA NA Nephrology, hematopoeisis Conference Presentations and Lectures
2008 Iskedjian M, Walker JH, De Serres G, Einarson TR. Economic and clinical impact of implementation of an acellular pertussis vaccine in Canada. ISPOR 11th Annual European Congress, Athens, Greece, November 8-11, 2008 NA NA NA Infectious Diseases Conference Presentations and Lectures
2008 Iskedjian M. Fundamentals of health economics and policy implications. Merck Health Economics Workshop, Lima, Peru, March 2008 NA NA NA Health Policy Conference Presentations and Lectures
2008 Einarson TR, Walker JH, Machado M, Iskedjian M. Meta-analysis of selected anitconvulsants, SNRIs and TCAs in treating neuropathic pain. ISPOR 13th Annual International Meeting, Toronto, ON, Canada, May 2008 NA NA NA CNS/Neurology Conference Presentations and Lectures
2008 Wang M, Iyer S, Desjardins O, Iskedjian M, Einarson TR. Treatment preference and willingness to pay (WTP) for methylnaltrexone, a novel peripheral opioid antagonist for opioid induced constipation. ISPOR 11th Annual European Congress, Athens, Greece, November 8-11, 2008 NA NA NA Gasteroenterology Conference Presentations and Lectures
2008 Iskedjian M, Walker JH, Desjardins O, Covert D, Einarson TR. Prostaglandin agonist use with and without adjunctive therapy for the treatment of glaucoma: A Canadian population based analysis. ISPOR 9th Annual European Meeting, Copenhagen, Denmark, October 2006 NA NA NA Ophthalmology, Prostaglandin Therapeutics Conference Presentations and Lectures
2008 Iskedjian M, Walker JH, Einarson TR, Desjardins O, Herings RMC, Sukel MPP, Covert D. Prostaglandin agonist use with and without adjunctive therapy for the treatment of glaucoma: A Netherlands population based analysis. ISPOR 13th Annual International Meeting, Toronto, ON, Canada, May 2008 NA NA NA Ophthalmology, Prostaglandin Therapeutics Conference Presentations and Lectures
2008 Hayward A, Roggenbach M, Purdy C, Caruana D, Einarson TR, Iskedjian M. The development of a standardized clinical algorithmic p#2461aaictor of weight loss after bariatric surgery: Database analysis enables empirical and statistical p#2461aaiction of threshold weight loss by end of third post-operative physician visit. ISPOR 13th Annual International Meeting, Toronto, ON, Canada, May 2008 NA NA NA Obesity Conference Presentations and Lectures
2008 Purdy CH, Hayward A, Magar RS, Iskedjian M. Incremental savings associated with a decrease in antidepressant medications following bariatric surgery in western New York. ISPOR 11th Annual European Congress, Athens, Greece, November 8-11, 2008 NA NA NA Obesity, CNS/Psychiatry Conference Presentations and Lectures
2007 Einarson T, Machado M, Walker J, Iskedjian M. Comment on: The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease. Current Medical Research and Opinion 23 7 1571-1573 Gasteroenterology Peer-Reviewed Journal Article
2007 Iskedjian M, Bereza B, Gordon A, Piwko C, Einarson TR. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Current Medical Research and Opinion 23 1 17-24 CNS/Neurology Peer-Reviewed Journal Article
2007 Piwko C, Desjardins O, Bereza BG, Machado M, Jaszewski B, Freedman MS, Einarson TR, Iskedjian M. Pain due to multiple sclerosis: Analysis of the prevalence and economic burden in Canada. Pain Research & Management: The journal of the Canadian Pain Society 12 4 259-265 CNS/Neurology Peer-Reviewed Journal Article
2007 Machado M, Iskedjian M, Ruiz IA, Einarson TR. The economic impact of introducing SNRIs into the Brazilian national drug formulary: Cost-effectiveness and budget-impact analyses. PharmacoEconomics 25 11 979-990 CNS/Psychiatry Peer-Reviewed Journal Article
2007 Iskedjian M, Walker JH, Desjardins O, Einarson TR, Covert D. Adjunctive therapy use by glaucoma patients on oral antihypertensives. Value in Health 10 3 A145 Ophthalmology Abstract
2007 Machado M, Iskedjian M, Einarson TR. Justifying the use of cost minimization analysis: Reporting comparators’ equivalence. Value in Health 10 3 A191 Pharmacoeconomic Methods Abstract
2007 Iskedjian M, Walker JH, Desjardins O, Einarson TR, Covert D, Le Lorier J. Persistent prostaglandin agonist use with and without adjunctive therapy in glaucoma patients: A Canadian population based analysis. Pharmacoepidemiology and Drug Safety 16 NA S105 Ophthalmology, Prostaglandin Therapeutics Abstract
2007 Walker J, Krementchutzky M, Iskedjian M, Adams JE, Einarson TR. Pharmacoeconomic evaluation of Avonex®, Betaseron®, and best supportive care in MS patients following a clinically isolated syndrome. Canadian Journal of Clinical Pharmacology 14 2 e144 CNS/Psychiatry Abstract
2007 Piwko C, Poisson M, Stiver G, Machado M, Costei A, Vicente C, Fontaine L, Einarson TR, Roscoe D, Iskedjian M. Retrospective analysis of health care resource utilization and costs associated with methicillin resistant Staphylococcus aureus (MRSA) complicated skin and skin structure infections. Canadian Journal of Clinical Pharmacology 14 2 e114 Infectious Diseases Abstract
2007 Iskedjian M, Walker JH, Desjardins O, Einarson TR, Covert D. Adjunctive therapy use by glaucoma patients on oral antihypertensives. ISPOR 12th Annual International Meeting, Arlington, VA, May 19-23, 2007 NA NA NA Ophthalmology Conference Presentations and Lectures
2007 Iskedjian M, Einarson TR. Cost of illness analysis: what, how, and what for? Roswell Park Cancer Institute, Buffalo, NY, May 2007 NA NA NA Pharmacoeconomic Methods Conference Presentations and Lectures
2007 Robin AL, Iskedjian M, Walker JH, Desjardins O, Einarson TR, Covert DW. Does the presence of systemic medications impact on the use of glaucoma adjunctive therapies? A Canadian population based analysis. American Academy of Ophthalmology (AAO) 2007 Annual Meeting, New Orleans, Louisiana, November 10 - 13, 2007 NA NA NA Ophthalmology Conference Presentations and Lectures
2007 Machado M, Iskedjian M, Einarson TR. Justifying the use of cost minimization analysis: Reporting comparators’ equivalence. ISPOR 12th Annual International Meeting, Arlington, VA, May 19-23, 2007 NA NA NA Pharmacoeconomic Methods Conference Presentations and Lectures
2007 Iskedjian M, Walker JH, Desjardins O, Einarson TR, Covert D, Le Lorier J. Persistent prostaglandin agonist use with and without adjunctive therapy in glaucoma patients: A Canadian population based analysis. 23rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Quebec City, QC, Canada, August 2007 NA NA NA Ophthalmology, Prostaglandin Therapeutics Conference Presentations and Lectures
2007 Walker J, Krementchutzky M, Iskedjian M, Adams JE, Einarson TR. Pharmacoeconomic evaluation of Avonex®, Betaseron®, and best supportive care in MS patients following a clinically isolated syndrome. 4th Canadian Therapeutics Congress, Halifax, NS, Canada, May 2007 NA NA NA CNS/Neurology Conference Presentations and Lectures
2007 Piwko C, Poisson M, Stiver G, Machado M, Costei A, Vicente C, Fontaine L, Einarson TR, Roscoe D, Iskedjian M. Retrospective analysis of health care resource utilization and costs associated with methicillin resistant Staphylococcus aureus (MRSA) complicated skin and skin structure infections. 4th Canadian Therapeutics Congress, Halifax, NS, Canada, May 2007 NA NA NA Infectious Diseases Conference Presentations and Lectures
2006 Machado M, Iskedjian M, Einarson TR. Quality assessment of published health economic analyses from South America. Annals of Pharmacotherapy 40 5 943-949 Pharmacoeconomic Methods Peer-Reviewed Journal Article
2006 Machado M, Iskedjian M, Ruiz I, Einarson TR. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: A meta-analysis of head-to-head trials. Current Medical Research and Opinion 22 9 1825-1837 CNS/Psychiatry Peer-Reviewed Journal Article
2006 Einarson TR, Vicente C, Machado M, Covert D, Trope G, Iskedjian M. Screening for glaucoma in Canada: A systematic review of the literature. Canadian Journal of Ophthalmology 41 6 709-721 Ophthalmology Peer-Reviewed Journal Article
2006 Iskedjian M, Bereza B, Desjardins O, Jaszewski B, Piwko C, Einarson T. Converting the scores of a clinical instrument for measuring pain to a preference based one. Value in Health 9 3 A6 Pharmacoeconomic Methods Abstract
2006 Piwko C, Desjardins O, Bereza B, Jazsewski B, Iskedjian M, Einarson T. Economic burden of pain due to multiple sclerosis in Canada. Value in Health 9 3 A84 CNS/Neurology Abstract
2006 Machado M, Iskedjian M, Einarson T. Meta-analysis of SNRIs, SSRIs, and TCAs in the treatment of major depressive disorder using remission as the clinical outcome. Value in Health 9 3 A65 CNS/Psychiatry Abstract
2006 Machado M, Iskedjian M, Ruiz I, Einarson TR. Pharmacoeconomic analysis of antidepressants in Brazil. Value in Health 9 6 A313 CNS/Psychiatry Abstract
2006 Desjardins O, Bereza B, Jaszewski B, Malmberg C, Iskedjian M, Einarson TR, Piwko C. The prevalence and management of pain due to multiple sclerosis in Canada. Proceedings of the Consortium of Multiple Sclerosis Centers 2006 Annual Meeting, Scottsdale, AZ, May 2006 NA NA NA CNS/Neurology Abstract
2006 Iskedjian M, Piwko C, Desjardins O, Bereza B, Jaszewski B, Einarson TR, Gafni A. Treatment of neuropathic pain in multiple sclerosis: A population based willingness to pay analysis. Value in Health 9 6 A378 CNS/Neurology Abstract
2006 Iskedjian M, Machado M, Costei A, Vicente C, Han D, Einarson TR, Piwko C. Treatment patterns and outcomes associated with multidrug resistant Staphylococcus aureus infections (MRSA) in Canadian teaching hospitals: Interim analysis. Value in Health 9 6 A305 Infectious Diseases Abstract
2006 Iskedjian M, Bereza B, Desjardins O, Jaszewski B, Piwko C, Einarson T. Converting the scores of a clinical instrument for measuring pain to a preference based one. ISPOR 11th Annual International Meeting, Philadelphia, PA, May 2006 NA NA NA Pharmacoeconomic Methods Conference Presentations and Lectures
2006 Piwko C, Desjardins O, Bereza B, Jazsewski B, Iskedjian M, Einarson T. Economic burden of pain due to multiple sclerosis in Canada. ISPOR 11th Annual International Meeting, Philadelphia, PA, May 2006 NA NA NA CNS/Neurology Conference Presentations and Lectures
2006 Machado M, Iskedjian M, Einarson T. Meta-analysis of SNRIs, SSRIs, and TCAs in the treatment of major depressive disorder using remission as the clinical outcome. ISPOR 11th Annual International Meeting, Philadelphia, PA, May 2006 NA NA NA CNS/Psychiatry Conference Presentations and Lectures
2006 Machado M, Iskedjian M, Ruiz I, Einarson TR. Pharmacoeconomic analysis of antidepressants in Brazil. ISPOR 9th Annual European Meeting, Copenhagen, Denmark, October 2006 NA NA NA CNS/Psychiatry Conference Presentations and Lectures
2006 Machado M, Iskedjian M, Einarson TR. Quality assessment of published health economic analyses from South America. ISPOR 1st Latin America Conference, Cartagena, Colombia, September 2007 NA NA NA Pharmacoeconomic Methods Conference Presentations and Lectures
2006 Desjardins O, Bereza B, Jaszewski B, Malmberg C, Iskedjian M, Einarson TR, Piwko C. The prevalence and management of pain due to multiple sclerosis in Canada. Consortium of Multiple Sclerosis Centers 2006 Annual Meeting, Scottsdale, AZ, May 31 - June 3, 2006 NA NA NA CNS/Neurology Conference Presentations and Lectures
2006 Iskedjian M, Piwko C, Desjardins O, Bereza B, Jaszewski B, Einarson TR, Gafni A. Treatment of neuropathic pain in multiple sclerosis: A population based willingness to pay analysis. ISPOR 9th Annual European Meeting, Copenhagen, Denmark, October 2006 NA NA NA CNS/Neurology Conference Presentations and Lectures
2006 Iskedjian M, Machado M, Costei A, Vicente C, Han D, Einarson TR, Piwko C. Treatment patterns and outcomes associated with multidrug resistant Staphylococcus aureus infections (MRSA) in Canadian teaching hospitals: Interim analysis. ISPOR 9th Annual European Meeting, Copenhagen, Denmark, October 2006 NA NA NA Infectious Diseases Conference Presentations and Lectures
2005 Iskedjian M, Walker JH, De Serres G, Einarson TR. Economic evaluation of an extended acellular pertussis vaccine program for adolescents in Québec, Canada. Paediatric Drugs 7 2 123-136 Infectious Diseases Peer-Reviewed Journal Article
2005 Walker JH, Buys Y, Trope GE, Vicente C, Einarson TR, Covert D, Iskedjian M. Association between corneal thickness, mean intraocular pressure, disease stability and severity, and cost of treatment in glaucoma. Current Medical Research and Opinion 21 4 489-494 Ophthalmology Peer-Reviewed Journal Article
2005 Einarson TR, Granton JT, Vicente C, Walker JH, Engel G, Iskedjian M. Cost-effectiveness of treprostinil versus epoprostenol in patients with pulmonary arterial hypertension: A Canadian analysis. Canadian Respiratory Journal 12 8 419-425 Cardio-Respiratory Peer-Reviewed Journal Article
2005 Narine L, Hague LK, Walker JH, Vicente C, Schilz R, Desjardins O, Einarson TR, Iskedjian M. Cost-minimization analysis of treprostinil vs. epoprostenol as an alternate to oral therapy non-responders for the treatment of pulmonary arterial hypertension. Current Medical Research and Opinion 21 12 2007-2016 Cardio-Respiratory Peer-Reviewed Journal Article
2005 Iskedjian M, Walker JH, Gray T, Vicente C, Einarson TR, Gehshan A. Economic evaluation of Avonex® (Interferon beta-1a) in patients following a single demyelinating event. Multiple Sclerosis 11 5 542-555 CNS/Neurology Peer-Reviewed Journal Article
2005 Machado M, Iskedjian M, Einarson TR. Clinical comparison of SSRIs and SNRIs in major depressive disorder: A meta-analysis. Value in Health 8 6 A209 CNS/Psychiatry Abstract
2005 Walker JH, Bereza B, Hemels MEH, Le Melledo JM, Iskedjian M, Einarson TR. Cost effectiveness of escitalopram in the treatment of generalized anxiety disorder (GAD). Value in Health 8 6 A195 CNS/Psychiatry Abstract
2005 Iskedjian M, Barkovsky L, Desjardins O, Walker JH, Dorkalam M, Shear N, Einarson TR. Cost-effectiveness analysis of AmeviveTM (alefacept) in the treatment of patients with moderate-to-severe psoriasis. Value in Health 8 3 330 Dermatology Abstract
2005 Piwko C, Walker JH, Iskedjian M, Einarson TR. Cost-effectiveness of pegylated interferon treatments for chronic hepatitis C (HCV) patients in Canada. Canadian Journal of Clinical Pharmacology 12 1 e65 Infectious Diseases Abstract
2005 Iskedjian M, Barkovsky L, Desjardins O, Walker JH, Dorkalam M, Shear N, Einarson TR. Cost-utility analysis of AmeviveTM (alefacept) in the treatment of patients with moderate-to-severe psoriasis. Value in Health 8 3 331 Dermatology Abstract
2005 Einarson TR, Piwko C, Desjardins O, Tan J, Shear N, Dorkalam M, Iskedjian M. Economic burden of moderate to severe chronic-plaque psoriasis in Canada. Canadian Journal of Clinical Pharmacology 12 1 e75 Dermatology Abstract
2005 Machado M, Einarson TR, Iskedjian M. Health economic analyses in South America: Analysis of the literature. Pharmacoepidemiology and Drug Safety 14 S2 S118 Pharmacoeconomic Methods Abstract
2005 Piwko C, Iskedjian M, Desjardins O, Einarson TR. Medication and pharmacological treatment of nausea and vomiting in pregnancy: An unmet need? Pharmacoepidemiology and Drug Safety 14 S2 S114 Obstetrics/Gynaecology Abstract
2005 Machado M, Iskedjian M, Einarson TR. Clinical comparison of SSRIs and SNRIs in major depressive disorder: A meta-analysis. ISPOR 8th Annual European Meeting, Florence, Italy, November 2005 NA NA NA CNS/Psychiatry Conference Presentations and Lectures
2005 Walker JH, Bereza B, Hemels MEH, Le Melledo JM, Iskedjian M, Einarson TR. Cost effectiveness of escitalopram in the treatment of generalized anxiety disorder (GAD). ISPOR 8th Annual European Meeting, Florence, Italy, November 2005 NA NA NA CNS/Psychiatry Conference Presentations and Lectures
2005 Iskedjian M, Barkovsky L, Desjardins O, Walker JH, Dorkalam M, Shear N, Einarson TR. Cost-effectiveness analysis of AmeviveTM (alefacept) in the treatment of patients with moderate-to-severe psoriasis. ISPOR 10th Annual International Meeting, Washington, DC, May 2005 NA NA NA Dermatology Conference Presentations and Lectures
2005 Piwko C, Walker JH, Iskedjian M, Einarson TR. Cost-effectiveness of pegylated interferon treatments for chronic hepatitis C (HCV) patients in Canada. Canadian Association for Population Therapeutics Annual Meeting, Vancouver, BC, Canada, April 2005 NA NA NA Infectious Diseases Conference Presentations and Lectures
2005 Iskedjian M, Barkovsky L, Desjardins O, Walker JH, Dorkalam M, Shear N, Einarson TR. Cost-utility analysis of AmeviveTM (alefacept) in the treatment of patients with moderate-to-severe psoriasis. ISPOR 10th Annual International Meeting, Washington, DC, May 2005 NA NA NA Dermatology Conference Presentations and Lectures
2005 Desjardins O, Piwko C, Bereza B, Gordon A, Devonshire V, Freedman M, Ursell M, Vicente C, Iskedjian M, Jaszewski B, Einarson TR, Gafni A. Development and pre-testing of a willingness to pay instrument for a treatment for pain in multiple sclerosis. Canadian Association for Health Services and Policy Research (CAHSR), Montreal, QC, Canada, September 2005 NA NA NA CNS/Neurology Conference Presentations and Lectures
2005 Einarson TR, Piwko C, Desjardins O, Tan J, Shear N, Dorkalam M, Iskedjian M. Economic burden of moderate to severe chronic plaque psoriasis in Canada. Canadian Association for Population Therapeutics Annual Meeting, Vancouver, BC, Canada, April 2005 NA NA NA Dermatology Conference Presentations and Lectures
2005 Walker JH, Einarson TR, Iskedjian M. Economic impact of patient non-adherence and its implications on Canada's healthcare system and pharmaceutical manufacturers. Patient Adherence Strategies Conference, Toronto, ON, Canada, October 2005 NA NA NA Adherence Conference Presentations and Lectures
2005 Machado M, Einarson TR, Iskedjian M. Health economic analyses in South America: Analysis of the literature. 21st International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Nashville, TN, August 2005 NA NA NA Pharmacoeconomic Methods Conference Presentations and Lectures
2005 Einarson TR, Iskedjian M. Incorporating economic and humanistic outcomes in clinical trials. Massachusetts Biotech Council, Clinical Trial Committee Seminar, Cambridge, MA, December 2005 NA NA NA Pharmacoeconomic Methods Conference Presentations and Lectures
2005 Piwko C, Iskedjian M, Desjardins O, Einarson TR. Medication and pharmacological treatment of nausea and vomiting in pregnancy: An unmet need? 21st International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Nashville, TN, August 2005 NA NA NA Obstetrics/Gynaecology Conference Presentations and Lectures
2005 Narine L, Einarson TR, Iskedjian M. Reimbursement and market possibilities for combination drugs in Canada. Provincial Reimbursement Advisor, May 2005 NA NA 49-54 Reimbursement Non-reviewed Publications
2004 Vicente C, Walker JH, Buys Y, Einarson TR, Covert D, Iskedjian M. Association between mean intraocular pressure, disease stability, and cost of treating glaucoma in Canada. Current Medical Research and Opinion 20 8 1245-1251 Ophthalmology Peer-Reviewed Journal Article
2004 Kumar RN, Gupchup GV, Dodd M, Shah B, Iskedjian M, Einarson TR, Raisch DW. Direct health care costs of four common skin ulcers in New Mexico Medicaid fee-for-service patients. Advances in Skin and Wound Care 17 3 143-149 Dermatology Peer-Reviewed Journal Article
2004 Iskedjian M, Hemels M, Walker JH. Economic evaluation of an extended acellular pertussis vaccine programme for adolescents in Ontario, Canada. Vaccine 22 31-32 4215-4227 Infectious Diseases Peer-Reviewed Journal Article
2004 Iskedjian M, Piwko C, Shear NH, Langley RGB, Einarson TR. Topical calcineurin inhibitors in the treatment of atopic dermatitis: A meta-analysis of current evidence. American Journal of Clinical Dermatology 5 4 267-279 Dermatology Peer-Reviewed Journal Article
2004 Walker JH, Buys Y, Trope GE, Vicente C, Einarson TR, Covert D, Iskedjian M. Association between corneal thickness, intraocular pressure, and disease stability in primary open angle glaucoma. Investigative Ophthalmology and Visual Science 45 E-Abstract 4497 Ophthalmology Abstract
2004 Iskedjian M, Walker J, Gray T, Vicente C, Einarson T, Gehshan A. Cost effectiveness analysis of interferon beta-1A (Avonex®) in pre-clinically definite multiple sclerosis (CDMS). Value in Health 7 3 290 CNS/Neurology Abstract
2004 Iskedjian M, Walker J, Gray T, Vicente C, Einarson T, Gehshan A. Cost utility analysis of interferon beta-1A (Avonex®) in pre-clinically definite multiple sclerosis (CDMS). Value in Health 7 3 291 CNS/Neurology Abstract
2004 Narine L, Hague LK, Vicente C, Walker J, Einarson TR, Iskedjian M. Cost-effectiveness of treprostinil vs. epoprostenol in patients with pulmonary arterial hypertension. Proceedings of the American Thoracic Society 100th Annual International Conference, Orlando, FL, May 2004 NA NA NA Cardio-Respiratory Abstract
2004 Iskedjian M, Walker J, Gray T, Vicente C, Einarson TR, Gehshan A. Economic evaluation of Avonex® in pre-clinically definite multiple sclerosis. Proceedings of the Consortium of Multiple Sclerosis Centers 2004 Annual Meeting, Toronto, ON, Canada, June 2004 NA NA NA CNS/Neurology Abstract
2004 Piwko C, Iskedjian M, Walker JH, Einarson TR, Merikle E. Economic impact of improved adherence in the treatment of dyslipidemia in Canada. Canadian Journal of Clinical Pharmacology 11 1 e104 Cardiovascular, adherence Abstract
2004 Iskedjian M, Piwko C, Walker JH, Einarson TR, Merikle E. Economic impact of improved adherence in the treatment of hypertension in Canada. Canadian Journal of Clinical Pharmacology 11 1 e105 Cardiovascular, adherence Abstract
2004 Einarson TR, Barkovsky L, Lipton JH, Iskedjian M. Evidence-based review of antifungal agents for prophylaxis or treatment of systemic fungal infections In patients with neutropenia. Proceedings of the Infectious Diseases Society of America (IDSA), Boston, MA, September 30 - October 3, 2004 NA NA NA Infectious Diseases Abstract
2004 Iskedjian M, Rotstein C, Barkovsky L, Einarson TR. Evidence-based review of antifungal agents for prophylaxis or treatment of systemic fungal infections In patients without neutropenia. Proceedings of the Infectious Diseases Society of America (IDSA), Boston, MA, September 30 - October 3, 2004 NA NA NA Infectious Diseases Abstract
2004 Iskedjian M, Einarson TR, Hemels MH, Fleshner N, Iscoe N. Evidence-based review of luteinizing hormone releasing hormone (LHRH) agonists in metastatic prostate cancer. Pharmacoepidemiology and Drug Safety 13 S1 S219 Oncology Abstract
2004 Iskedjian M, Einarson TR, Barkovsky L, Lipton J. Systemic antifungal agents in neutropenic patients: A meta-analysis of the evidence. Conference Proceedings, Infectious Diseases Society of America (IDSA) 42nd Annual Meeting, September 30 – October 3, 2004 NA NA 175 Infectious Diseases Abstract
2004 Iskedjian M, Einarson TR, Barkovsky L, Rotstein C. Systemic antifungal agents in non-neutropenic patients: A meta-analysis of the evidence. Conference Proceedings, Infectious Diseases Society of America (IDSA) 42nd Annual Meeting, September 30 - October 3, 2004 NA NA 164 Infectious Diseases Abstract
2004 Walker JH, Buys Y, Trope GE, Vicente C, Einarson TR, Covert D, Iskedjian M. Association between corneal thickness, intraocular pressure, and disease stability in primary open angle glaucoma. ARVO Annual Meeting, Orlando, FL, April 2004 NA NA NA Ophthalmology Conference Presentations and Lectures
2004 Iskedjian M, Walker J, Gray T, Vicente C, Einarson T, Gehshan A. Cost effectiveness analysis of interferon beta-1A (Avonex®) in pre-clinically definite multiple sclerosis (CDMS). ISPOR 9th Annual International Meeting, Crystal City-Washington, DC, May 2004 NA NA NA CNS/Neurology Conference Presentations and Lectures
2004 Iskedjian M. Cost of illness analysis: Top down or bottom up? Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon, October 2004 NA NA NA Pharmacoeconomic Methods Conference Presentations and Lectures
2004 Iskedjian M, Walker J, Gray T, Vicente C, Einarson T, Gehshan A. Cost utility analysis of interferon beta-1A (Avonex®) in pre-clinically definite multiple sclerosis (CDMS). ISPOR 9th Annual International Meeting, Crystal City-Washington, DC, May 2004 NA NA NA CNS/Neurology Conference Presentations and Lectures
2004 Narine L, Hague LK, Vicente C, Walker J, Einarson TR, Iskedjian M. Cost-effectiveness of treprostinil vs. epoprostenol in patients with pulmonary arterial hypertension. American Thoracic Society 100th Annual International Conference, Orlando, FL, May 2004 NA NA NA Cardio-Respiratory Conference Presentations and Lectures
2004 Iskedjian M, Walker J, Gray T, Vicente C, Einarson TR , Gehshan A. Economic evaluation of Avonex® in pre-clinically definite multiple sclerosis. Consortium of Multiple Sclerosis Centers 2004 Annual Meeting, Toronto, ON, Canada, June 2004 NA NA NA CNS/Neurology Conference Presentations and Lectures
2004 Piwko C, Iskedjian M, Walker JH, Einarson TR, Merikle E. Economic impact of improved adherence in the treatment of dyslipidemia in Canada. Canadian Association for Population Therapeutics Annual Meeting, Winnipeg, MB, Canada, June 2004 NA NA NA Cardiovascular, adherence Conference Presentations and Lectures
2004 Iskedjian M, Piwko C, Walker JH, Einarson TR, Merikle E. Economic impact of improved adherence in the treatment of hypertension in Canada. Canadian Association for Population Therapeutics Annual Meeting, Winnipeg, MB, Canada, June 2004 NA NA NA Cardiovascular, adherence Conference Presentations and Lectures
2004 Einarson TR, Barkovsky L, Lipton JH, Iskedjian M. Evidence-based review of antifungal agents for prophylaxis or treatment of systemic fungal infections In patients with neutropenia. Infectious Diseases Society of America (IDSA), Boston, MA, September 30 - October 3, 2004 NA NA NA Infectious Diseases Conference Presentations and Lectures
2004 Iskedjian M, Rotstein C, Barkovsky L, Einarson TR. Evidence-based review of antifungal agents for prophylaxis or treatment of systemic fungal infections In patients without neutropenia. Infectious Diseases Society of America (IDSA) Boston, MA, September 30 - October 3, 2004 NA NA NA Infectious Diseases Conference Presentations and Lectures
2004 Iskedjian M, Einarson TR, Hemels MH, Fleshner N, Iscoe N. Evidence-based review of luteinizing hormone releasing hormone (LHRH) agonists in metastatic prostate cancer. 20th International Conference on Pharmacoepidemiology, Bordeaux, France, August 22-24, 2004 NA NA NA Oncology Conference Presentations and Lectures
2004 Iskedjian M. Implications of the perspective in cost of illness analysis: The example of glaucoma in Canada. Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon, October 2004 NA NA NA Glaucoma, Pharmacoeconomic Methods Conference Presentations and Lectures
2004 Iskedjian M, Einarson TR, Barkovsky L, Lipton J. Systemic antifungal agents in neutropenic patients: A meta-analysis of the evidence. Infectious Diseases Society of America (IDSA) 42nd Annual Meeting, September 30 – October 3, 2004 NA NA NA Infectious Diseases Conference Presentations and Lectures
2004 Iskedjian M, Einarson TR, Barkovsky L, Rotstein C. Systemic antifungal agents in non-neutropenic patients: A meta-analysis of the evidence. Infectious Diseases Society of America (IDSA) 42nd Annual Meeting, September 30 - October 3, 2004 NA NA NA Infectious Diseases Conference Presentations and Lectures
2004 Narine L, Iskedjian M. Managing the cost of cancer drugs. Provincial Reimbursement Advisor, November 2004 NA NA 37-41 Oncology Non-reviewed Publications
2003 Iskedjian M, Einarson TR. Cost analysis of ropinirole versus levodopa in the treatment of Parkinson’s disease. PharmacoEconomics 21 2 115-127 CNS/Neurology Peer-Reviewed Journal Article
2003 Iskedjian M, Walker J, Vicente C, Trope G, Buys Y, Einarson TR, Covert D. Cost of glaucoma in Canada: Analyses based on visual field and physician’s assessment. Journal of Glaucoma 12 6 456-462 Ophthalmology Peer-Reviewed Journal Article
2003 Iskedjian M, Hemels M, Einarson TR, Vicente C, Iscoe N, Fleshner N. Review of luteinizing hormone-releasing hormone agonists in non-adjuvant therapy for advanced prostate cancer. Canadian Coordinating Office for Health Technology Assessment (CCOHTA), Ottawa NA 44 NA Oncology Peer-Reviewed Report
2003 Iskedjian M, Maturi B, Walker JH, Einarson TR, Khattak S, Carter G. Cost-effectiveness of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adolescents. Value in Health 6 3 275 CNS/Psychiatry Abstract
2003 Iskedjian M, Piwko C, Walker JH, Vicente C, Einarson TR. Do controlled trials of adherence to antihypertensive drugs generate higher rates? Evidence from the literature. Proceedings of the ISPOR 1st Asia-Pacific Meeting, Kobe, Japan, September 2003 NA NA 12 Adherence, Cardiovascular Abstract
2003 Iskedjian M, Hemels M, Walker JH. Economic evaluation of an extended acellular pertussis vaccine programme for adolescents in Ontario, Canada. Canadian Journal of Clinical Pharmacology 10 1 37 Infectious Diseases Abstract
2003 Khattak S, Carter G, Maturi B, Walker JH, Einarson TR, Iskedjian M. Patient preferences for nonstimulant therapy over stimulants in attention deficit hyperactivity disorder: A pharmaco-epidemiologic pilot study. Canadian Journal of Clinical Pharmacology 10 3 158 CNS/Psychiatry Abstract
2003 Iskedjian M, De Serres G, Walker JH, Einarson TR. Pertussis vaccination in adolescents: Costs and consequences of a proposed vaccination programme in Québec, Canada. Canadian Journal of Clinical Pharmacology 10 1 45 Infectious Diseases Abstract
2003 Iskedjian M, Walker JH, De Serres G, Einarson TR, Hemels M. Pertussis vaccination in adolescents: Costs and consequences of new proposed vaccination programmes in Canada. Value in Health 6 3 266 Infectious Diseases Abstract
2003 Iskedjian M, Walker J, Hemels M, Maturi B, Einarson TR. Pertussis vaccination in adolescents: costs and consequences of new proposed vaccination programmes in four Canadian provinces. Proceedings of the ISPOR 1st Asia-Pacific Meeting, Kobe, Japan, September 2003 NA NA 20 Infectious Diseases Abstract
2003 Vicente C, Walker J, Trope G, Buys Y, Einarson TR, Covert D, Iskedjian M. Association between mean intra-ocular pressure, disease stability, and cost of treatment in glaucoma. Annual Meeting of the Canadian Ophthalmological Society, Halifax, NS, Canada, June 2003 NA NA NA Ophthalmology Conference Presentations and Lectures
2003 Einarson TR, Iskedjian M. Cost of illness analysis: top down or bottom up? ISPOR 1st Asia-Pacific Meeting, Kobe, Japan, September 2003 NA NA NA Pharmacoeconomic Methods Conference Presentations and Lectures
2003 Iskedjian M, Maturi B, Walker J, Khattak S, Carter G, Einarson TR. Cost-effectiveness of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adolescents. ISPOR 8th Annual International Meeting, Crystal City-Washington, DC, May 2003 NA NA NA CNS/Psychiatry Conference Presentations and Lectures
2003 Iskedjian M, Piwko C, Walker JH, Vicente C, Einarson TR. Do controlled trials of adherence to antihypertensive drugs generate higher rates? Evidence from the literature. ISPOR 1st Asia-Pacific Meeting, Kobe, Japan, September 2003 NA NA NA Adherence, Cardiovascular Conference Presentations and Lectures
2003 Iskedjian M, Hemels M, Walker JH. Economic evaluation of an extended acellular pertussis vaccine programme for adolescents in Ontario, Canada. Canadian Association for Population Therapeutics Annual Meeting, Quebec City, QC, Canada, April 2003 NA NA NA Infectious Diseases Conference Presentations and Lectures
2003 Khattak S, Carter G, Maturi B, Walker JH, Einarson TR, Iskedjian M. Patient preferences for nonstimulant therapy over stimulants in attention deficit hyperactivity disorder: A pharmaco-epidemiologic pilot study. Canadian Society for Clinical Pharmacology 25th Anniversary Conference, Ottawa, ON, Canada, September 2003 NA NA NA CNS/Psychiatry Conference Presentations and Lectures
2003 Iskedjian M, De Serres G, Walker JH, Einarson TR. Pertussis vaccination in adolescents: Costs and consequences of a proposed vaccination programme in Québec, Canada. Canadian Association for Population Therapeutics Annual Meeting, Quebec City, QC, Canada, April 2003 NA NA NA Infectious Diseases Conference Presentations and Lectures
2003 Iskedjian M, Walker JH, De Serres G, Einarson TR, Hemels M. Pertussis vaccination in adolescents: Costs and consequences of new proposed vaccination programmes in Canada. ISPOR 8th Annual International Meeting, Crystal City-Washington, DC, May 2003 NA NA NA Infectious Diseases Conference Presentations and Lectures
2003 Iskedjian M, Walker J, Hemels M, Maturi B, Einarson TR. Pertussis vaccination in adolescents: costs and consequences of new proposed vaccination programmes in four Canadian provinces. ISPOR 1st Asia-Pacific Meeting, Kobe, Japan, September 2003 NA NA NA Infectious Diseases Conference Presentations and Lectures
2003 Iskedjian M. Estimating the burden of prescription drug non-adherence in Canada. Canadian Healthcare Manager, June 2003 NA NA NA Adherence Non-reviewed Publications
2002 Einarson TR, Metge CJ, Iskedjian M, Mukherjee J. An examination of the effect of cytochrome P450 drug interactions of hydroxymethylglutaryl-coenzyme A #2461aauctase inhibitors on healthcare utilization: A Canadian population-based study. Clinical Therapeutics 24 12 2126-2136 Drug Interactions Peer-Reviewed Journal Article
2002 Oh PI, Iskedjian M, Addis A, Lanctôt K, Einarson TR. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: A cost-utility analysis. Canadian Journal of Clinical Pharmacology 8 4 199-206 CNS/Psychiatry Peer-Reviewed Journal Article
2002 Iskedjian M, Einarson TR, MacKeigan LD, Shear N, Addis A, Mittmann N, Ilersich AL. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: Evidence from a meta-analysis. Clinical Therapeutics 24 2 302-316 Cardiovascular, Adherence, Compliance Peer-Reviewed Journal Article
2002 Iskedjian M, Walker JH, Vicente C, Trope G, Buys Y, Einarson TR, Covert D. Cost of illness of glaucoma in Canada: Analyses based on visual field measurements and physician’s assessment. Value in Health 5 6 551 Ophthalmology Abstract
2002 Hemels M, Iskedjian M, Iscoe N, Fleshner N, Einarson TR. Cost utility analysis of LHRH agonists in metastatic prostate cancer. Value in Health 5 3 129 Oncology Abstract
2002 Iskedjian M, Hemels M, Iscoe N, Fleshner N, Einarson TR. Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer. Value in Health 5 3 196 Oncology Abstract
2002 Chabot I, Yin DD, Iskedjian M, Chapados S. Effect of inappropriate initial antibiotic therapy on outcomes of patients hospitalized with complicated intra-abdominal infections in Canada. Proceedings of the Infectious Diseases Society of America 40th Annual Meeting, Chicago, IL, October 2002 NA NA NA Infectious Diseases Abstract
2002 Iskedjian M, Addis A, Einarson TR. Estimating the economic burden of hospitalization due to patient nonadherence in Canada. Value in Health 5 6 470 Adherence Abstract
2002 Iskedjian M, Hemels M, Molloy W, Fornazzari L, Einarson TR. Evidence based review of the use of novel antipsychotics in treating dementia-associated agitation. Canadian Journal of Clinical Pharmacology 9 1 35 CNS/Psychiatry Abstract
2002 Hemels M, Iskedjian M, Iscoe N, Fleshner N, Einarson TR. LHRH agonists in the treatment of metastatic prostate cancer: Meta-analysis of the evidence. Canadian Journal of Clinical Pharmacology 9 1 40 Oncology Abstract
2002 Hemels M, Iskedjian M, Iscoe N, Fleshner N, Einarson TR. Meta-analysis of LHRH agonists efficacy in the treatment of metastatic prostate cancer. Value in Health 5 3 176 Oncology Abstract
2002 Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. Journal of the American Medical Association 287 4 455-463 CNS/Neurology Acknowledgement
2002 Iskedjian M, Walker JH, Vicente C, Trope G, Buys Y, Einarson TR, Covert D. Cost of illness of glaucoma in Canada: Analyses based on visual field measurements and physician’s assessment. ISPOR 5th Annual European Meeting, Rotterdam, The Netherlands, November 2002 NA NA NA Ophthalmology Conference Presentations and Lectures
2002 Hemels M, Iskedjian M, Iscoe N, Fleshner N, Einarson TR. Cost utility analysis of LHRH agonists in metastatic prostate cancer. ISPOR 7th Annual International Meeting, Crystal City-Washington, DC, May 2002 NA NA NA Oncology Conference Presentations and Lectures
2002 Iskedjian M, Hemels M, Iscoe N, Fleshner N, Einarson TR. Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer. ISPOR 7th Annual International Meeting, Crystal City-Washington, DC, May 2002 NA NA NA Oncology Conference Presentations and Lectures
2002 Iskedjian M, Einarson TR. Economic evaluations of vaccination programmes for pertussis in Canada: I- evaluation in children up to age 6, II- evaluation in adolescents. Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon, October 2002 NA NA NA Infectious Diseases Conference Presentations and Lectures
2002 Chabot I, Yin DD, Iskedjian M, Chapados S. Effect of inappropriate initial antibiotic therapy on outcomes of patients hospitalized with complicated intra-abdominal infections in Canada. Infectious Diseases Society of America 40th Annual Meeting, Chicago, IL, October 2002 NA NA NA Infectious Diseases Conference Presentations and Lectures
2002 Iskedjian M, Einarson TR. Estimating the cost of nonadherence in Canada. Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon, November 2002 NA NA NA Adherence, Cost of Illness Conference Presentations and Lectures
2002 Iskedjian M, Addis A, Einarson TR. Estimating the economic burden of hospitalization due to patient nonadherence in Canada. ISPOR 5th Annual European Meeting, Rotterdam, The Netherlands, November 2002 NA NA NA Adherence, Cost of Illness Conference Presentations and Lectures
2002 Iskedjian M, Einarson TR. Estimation des coûts associés à la nonobservance au Canada. Faculté de Pharmacie, Université Saint-Joseph, Beirut, Lebanon, October 2002 NA NA NA Adherence, Cost of Illness Conference Presentations and Lectures
2002 Iskedjian M, Hemels M, Molloy W, Fornazzari L, Einarson TR. Evidence based review of the use of novel antipsychotics in treating dementia-associated agitation. Canadian Association for Population Therapeutics Annual Meeting, Toronto, ON, Canada, April 2002 NA NA NA CNS/Psychiatry Conference Presentations and Lectures
2002 Hemels M, Iskedjian M, Iscoe N, Fleshner N, Einarson TR. LHRH agonists in the treatment of metastatic prostate cancer: Meta-analysis of the evidence. Canadian Association for Population Therapeutics Annual Meeting, Toronto, ON, Canada, April 2002 NA NA NA Oncology Conference Presentations and Lectures
2002 Hemels M, Iskedjian M, Iscoe N, Fleshner N, Einarson TR. Meta-analysis of LHRH agonists efficacy in the treatment of metastatic prostate cancer. ISPOR 7th Annual International Meeting, May 2002 NA NA NA Oncology Conference Presentations and Lectures
2002 Iskedjian M, Einarson TR. Review of the Canadian guidelines for economic evaluation of pharmaceuticals. Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon, November 2002 NA NA NA Pharmacoeconomic Methods, HTA Conference Presentations and Lectures
2002 Einarson TR, Iskedjian M. Review of the clinical implications of nonadherence to pharmacotherapy. Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon, November 2002 NA NA NA Adherence, Compliance Conference Presentations and Lectures
2002 Einarson TR, Iskedjian M. Revue de l'impact clinique et économique de la nonobservance des traitements pharmaceutiques. Faculté de Pharmacie, Université Saint-Joseph, Beirut, Lebanon, October 2002 NA NA NA Adherence, Compliance Conference Presentations and Lectures
2002 Iskedjian M. The economic impact of patient nonadherence in Canada. Healthy Outcomes Conference, Lake Louise, AB, Canada, April 2002 NA NA NA Adherence, Compliance Conference Presentations and Lectures
2001 Marchetti A, Magar R, Lau H, Murphy E, Jensen PS, Conners CK, Findling R, Wineburg E, Carotenuto I, Einarson TR, Iskedjian M. Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis. Clinical Therapeutics 23 11 1904-1921 CNS/Psychiatry Peer-Reviewed Journal Article
2001 Hemels MEH, Lanctôt K, Iskedjian M, Einarson TR. Clinical and economic factors in the treatment of behavioral and psychological symptoms of dementia. Drugs and Aging 18 7 527-550 CNS/Psychiatry Peer-Reviewed Journal Article
2001 Oh PI, Lanctôt KL, Mittmann N, Iskedjian M, Einarson TR. Cost-utility of risperidone compa#2461aa with standard conventional antipsychotics in chronic schizophrenia. Journal of Medical Economics 4 NA 137-156 CNS/Psychiatry Peer-Reviewed Journal Article
2001 Iskedjian M, Einarson TR, O’Brien B, Des Serres G, Gemmill IM, Gold R, Milkovich N, Rosner A. Economic evaluation of a new acellular vaccine for pertussis in Canada. PharmacoEconomics 19 5 (Pt 2) 551-563 Infectious Diseases, Immunisation Peer-Reviewed Journal Article
2001 Joffe R, Iskedjian M, Einarson TR, O’Brien B, Stang MR. Examining the Saskatchewan Health drug database for antidepressant use: The case of fluoxetine. Canadian Journal of Clinical Pharmacology 8 3 146-152 CNS/Psychiatry Peer-Reviewed Journal Article
2001 Einarson TR, Iskedjian M. Novel antipsychotics for patients with attention-deficit hyperactivity disorder: A systematic review. Canadian Coordinating Office for Health Technology Assessment (CCOHTA), Ottawa, ON NA 17 NA CNS/Psychiatry Peer-Reviewed Report
2001 Hanna B, Iskedjian M, Carpenter S, Einarson TR, Maetzel A, Bennett H. Analysis of a cohort of patients with advanced rheumatoid arthritis using a practise based pharmacoepidemiologic database. Pharmacoepidemiology and Drug Safety 10 NA S160 Rheumatoid Arthritis Abstract
2001 Iskedjian M. Development and implementation of pharmacoeconomics in Canada. Proceedings of the 8th Armenian Medical World Congress, Toronto, ON, July 2001 NA NA NA Pharmacoeconomic Methods, HTA Abstract
2001 Iskedjian M, Einarson TR. Impact of luteinizing hormone releasing hormone agonists on the cytostatic drug market in Canada 1985-2000. Pharmacoepidemiology and Drug Safety 10 NA S136-S137 Oncology, Prostate Cancer Abstract
2001 Einarson TR, Iskedjian M. Lower daily dose frequency associated with higher patient adherence rates in hypertension. Proceedings of the 8th Armenian Medical World Congress, Toronto, ON, July 2001 NA NA NA Cardiovascular, Adherence, Compliance Abstract
2001 Iskedjian M, Aprahamian S, Einarson TR. The Musaler Health Study: A model for pidemiologic and pharmacoepidemiologic analyses - Part I: Feasibility phase. Proceedings of the 8th Armenian Medical World Congress, Toronto, ON, July 2001 NA NA NA Epidemiology, Pharmacoepidemiology Abstract
2001 Hanna B, Iskedjian M, Carpenter S, Einarson TR, Maetzel A, Bennett H. Analysis of a cohort of patients with advanced rheumatoid arthritis using a practise based pharmacoepidemiologic database. 17th International Conference on Pharmacoepidemiology, Toronto, ON, Canada, August 2001 NA NA NA Rheumatoid Arthritis Conference Presentations and Lectures
2001 Iskedjian M. Development and implementation of pharmacoeconomics in Canada. The 8th Armenian Medical World Congress, Toronto, ON, July 2001 NA NA NA Pharmacoeconomic Methods, HTA Conference Presentations and Lectures
2001 Iskedjian M, Einarson TR. Impact of luteinizing hormone releasing hormone agonists on the cytostatic drug market in Canada 1985-2000. 17th International Conference on Pharmacoepidemiology, Toronto, ON, Canada, August 2001 NA NA NA Oncology, Prostate Cancer Conference Presentations and Lectures
2001 Einarson TR, Iskedjian M. Lower daily dose frequency associated with higher patient adherence rates in hypertension. The 8th Armenian Medical World Congress, Toronto, ON, July 2001 NA NA NA Cardiovascular, Adherence, Compliance Conference Presentations and Lectures
2001 Iskedjian M, Aprahamian S, Einarson TR. The Musaler Health Study: A model for epidemiologic and pharmacoepidemiologic analyses - Part I: Feasibility phase. The 8th Armenian Medical World Congress, Toronto, ON, July 2001 NA NA NA Epidemiology, Pharmacoepidemiology Conference Presentations and Lectures
2000 Einarson TR, Kulin NA, Tingey D, Iskedjian M. Meta-analysis of the effect of latanoprost and brimonidine on intraocular pressure in the treatment of glaucoma. Clinical Therapeutics 22 12 1502-1515 Ophthalmology, Glaucoma Peer-Reviewed Journal Article
2000 Iskedjian M, Einarson TR, Kulin NA, Shane LG. Cost analysis of ropinirole (ReQuip®) versus levodopa+benserazide (Prolopa®) in the treatment of Parkinson’s disease. Canadian Journal of Neurological Sciences 27 Suppl. 2 NA CNS/Neurology Abstract
2000 Kumar RN, Gupchup GV, Dodd N, Iskedjian M, Einarson TR, Raisch DW. Health care utilization and costs associated with four categories of skin ulcers in New Mexico Medicaid patients. Value in Health 3 2 118 Dermatology, Wound Healing Abstract
2000 Tingey D, Einarson TR, Kulin NA, Iskedjian M. Meta-analysis of latanoprost and brimonidine in #2461aaucing intraocular pressure in the treatment of open-angle glaucoma and ocular hypertension. Canadian Journal of Ophthalmology 35 2 104 Ophthalmology, Glaucoma Abstract
2000 Iskedjian M, Metge CJ, Einarson TR, Yogendran M, Mukherjee J. Quantifying the impact of interactions between HMG-CoA #2461aauctase inhibitors (statins) and cytochrome P-450 interacting drugs on healthcare utilization: A population-based study. Value in Health 3 2 50 Drug Interactions, Dyslipidemia Abstract
2000 Iskedjian M, Einarson TR. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: Update of a meta-analysis. Value in Health 3 2 74 Cardiovascular, Adherence, Compliance Abstract
2000 Iskedjian M. Biotechnology and its impact on the pharmacist. University of Toronto, Toronto, ON, Canada, March 2000 NA NA NA Biopharmaceuticals, Biotechnology Conference Presentations and Lectures
2000 Iskedjian M, Einarson TR, Kulin NA, Shane LG. Cost analysis of ropinirole (ReQuip®) versus levodopa+benserazide (Prolopa®) in the treatment of Parkinson’s disease. 35th Meeting of the Canadian Congress of Neurological Sciences, Ottawa, ON, Canada, June 2000 NA NA NA CNS/Neurology Conference Presentations and Lectures
2000 Kumar RN, Gupchup GV, Dodd N, Iskedjian M, Einarson TR, Raisch DW. Health care utilization and costs associated with four categories of skin ulcers in New Mexico Medicaid patients. ISPOR 5th Annual International Meeting, Crystal City-Washington DC, May 2000 NA NA NA Dermatology, Wound Healing Conference Presentations and Lectures
2000 Tingey D, Einarson TR, Kulin NA, Iskedjian M. Meta-analysis of latanoprost and brimonidine in #2461aaucing intraocular pressure in the treatment of open-angle glaucoma and ocular hypertension. Annual Meeting of the Canadian Ophthalmological Society, Whistler, BC, Canada, June 2000 NA NA NA Ophthalmology, Glaucoma Conference Presentations and Lectures
2000 Iskedjian M, Einarson TR, Metge C, Yogendran M, Mukherjee J. Quantifying the impact of interactions between HMG-CoA #2461aauctase inhibitors (statins) and cytochrome P-450 interacting drugs on healthcare utilization: A population-based study. ISPOR 5th Annual International Meeting, Crystal City-Washington DC, May 2000 NA NA NA Drug Interactions, Dyslipidemia Conference Presentations and Lectures
2000 Metdge C, Iskedjian M, Einarson TR, Yogendran M, Mukherjee J. Quantifying the impact of interactions between HMG-CoA #2461aauctase inhibitors and cytochrome P-450 interacting drugs on healthcare utilization: A population-based study. Canada Association for Population Therapeutics, Montreal, QC, Canada, May 2000 NA NA NA Drug Interactions Conference Presentations and Lectures
2000 Iskedjian M, Einarson TR. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: Update of a meta-analysis. ISPOR 5th Annual International Meeting, Crystal City-Washington DC, May 2000 NA NA NA Cardiovascular, Adherence, Compliance Conference Presentations and Lectures
2000 Iskedjian M, Einarson TR, Metdge C, Yogendran M, Mukherjee J. Statin interactions: results of a Canadian population-based study. American College of Cardiology Satellite Symposium, Lake Louise, AB, March 2000 NA NA NA Cardiovascular, Dyslipidemia Conference Presentations and Lectures
1999 O’Brien BJ, Goeree R, Hux M, Iskedjian M, Blackhouse G, Gagnon M, Gauthier S. Economic evaluation of donepezil for the treatment of Alzheimer’s disease in Canada. Journal of the American Geriatrics Society 47 5 570-578 CNS/Psychiatry Peer-Reviewed Journal Article
1999 Iskedjian M, Oh P, Einarson TR, Lanctôt K, Addis A. Cost-utility analysis of risperidone in chronic schizophrenia. Value in Health 2 1 16 CNS/Psychiatry Abstract
1999 Iskedjian M, Joffe R, Einarson TR, O’Brien BJ, Stang MR, Lueck L. Review of fluoxetine use in Saskatchewan, Canada. Canadian Journal of Clinical Pharmacology 6 1 45 CNS/Psychiatry Abstract
1999 Iskedjian M. Drug databases: the good, the bad, and the ugly. Innovus Research Inc., Burlington, ON, Canada, September 1999 NA NA NA Pharmacovigilance, Pharmacoepidemiology Conference Presentations and Lectures
1999 Iskedjian M. Introduction to meta-analysis. Department of Clinical Pharmacology and Toxicology, Hospital for Sick Children, Toronto, ON, Canada, February 1999 NA NA NA Pharmacoeconomic Methods, HTA Conference Presentations and Lectures
1999 Iskedjian M. Pharmacoeconomics: needs and applications. Zentrallaboratorium Workshop, Brienz-Giessbach, Switzerland, October 1999 NA NA NA Pharmacoeconomic Methods, HTA Conference Presentations and Lectures
1999 Iskedjian M, Joffe R, Einarson TR, O’Brien BJ, Stang MR, Lueck L. Review of fluoxetine use in Saskatchewan, Canada. Canadian Forum for Population Therapeutics, Canadian Association for Population Therapeutics, Halifax, NS, May 1999 NA NA NA CNS/Psychiatry Conference Presentations and Lectures
1998 Iskedjian M, Einarson TR. Meta-analyses of cisapride, omeprazole and ranitidine in the treatment of GORD: Implications for treating patient subgroups. Clinical Drug Investigation 16 1 18-Sep Gasteroenterology, GERD Peer-Reviewed Journal Article
1998 Einarson TR, Addis A, Mittmann N, Iskedjian M. Meta-analysis of venlafaxine, SSRIs, and TCAs in the treatment of major depressive disorder. Canadian Journal of Clinical Pharmacology 5 4 205-216 CNS/Psychiatry Peer-Reviewed Journal Article
1998 Hux M, O’Brien B, Iskedjian M, Goeree R, Gagnon M, Gauthier S. Relationship between severity of Alzheimer’s disease and costs of caring. Canadian Medical Association Journal 159 5 457-465 CNS/Psychiatry Peer-Reviewed Journal Article
1998 Iskedjian M, Hux M, Remington GJ. The Canadian experience with risperidone for the treatment of schizophrenia: An overview. Journal of Psychiatry and Neuroscience 23 4 229-239 CNS/Psychiatry Peer-Reviewed Journal Article
1998 O’Brien BJ, Goeree R, Hux M, Iskedjian M, Blackhouse G, Gauthier S, Gagnon M. Economic evaluation of donepezil for the treatment of Alzheimer’s disease in Canada. Canadian Journal of Clinical Pharmacology 5 1 63 CNS/Psychiatry Abstract
1998 O'Brien B, Goeree R, Hux M, Iskedjian M, Blackhouse G, Gauthier S, Gagnon M. Economic evaluation of donepezil for treatment of Alzheimer's disease in Canada. Medical Decision Making 18 4 482 CNS/Psychiatry Abstract
1998 Iskedjian M, Addis A, Einarson TR. Estimating the cost of hospital admissions due to patient nonadherence in Ontario, Canada. Pharmacoepidemiology and Drug Safety 7 Supp S92-S93 Adherence, Compliance Abstract
1998 Einarson TR, Iskedjian M. Biotechnology: new drugs and their impact on society. Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada, February 1998 NA NA NA Biopharmaceuticals, Biotechnology Conference Presentations and Lectures
1998 Iskedjian M, Walker J. Cost Analysis. Innovus Research Inc., Burlington, ON, Canada, January 1998 NA NA NA Pharmacoeconomic Methods, HTA Conference Presentations and Lectures
1998 Iskedjian M, Oh P, Einarson TR, Lanctôt K, Addis A. Cost-utility analysis of risperidone in chronic schizophrenia. ISPOR Inaugural European Meeting, Koln, Germany, December 1998 NA NA NA CNS/Psychiatry Conference Presentations and Lectures
1998 Iskedjian M, Addis A, Einarson TR. Estimating the cost of hospital admissions due to patient nonadherence in Ontario, Canada. 14th International Conference on Pharmacoepidemiology, Berlin, Germany, August 1998 NA NA NA Adherence, Compliance Conference Presentations and Lectures
1998 Iskedjian M. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: Update on ongoing research. Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada, March 1998 NA NA NA Cardiovascular, Adherence, Compliance Conference Presentations and Lectures
1998 Iskedjian M, Einarson TR, Fassos FF. Pharmacoeconomic aspects of venlafaxine. Reviews in Contemporary Pharmacotherapy 9 5 345-353 CNS/Psychiatry Non-reviewed Publications
1998 Mittmann N, Trakas K, Iskedjian M, Bradley C, Einarson TR. A proposal for structu#2461aa abstracts of health economic studies. Annals of Pharmacotherapy 32 11 1244-1246 Pharmacoeconomic Methods Peer-Reviewed Journal Article
1997 Mittmann N, Liu BA, Iskedjian M, Bradley C, Pless R, Shear N, Einarson TR. Drug-related mortality in Canada (1984-1994). Pharmacoepidemiology and Drug Safety 6 3 157-168 Prescription Drug-Related Mortality, Pharmacoepidemiology Peer-Reviewed Journal Article
1997 Einarson TR, Addis A, Iskedjian M. Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder. PharmacoEconomics 12 2 (Pt 2) 286-296 CNS/Psychiatry Peer-Reviewed Journal Article
1997 Iskedjian M, Trakas K, Bradley CA, et al. Quality assessment of economic evaluations published in the journal PharmacoEconomics: The first four years (1992-1995). PharmacoEconomics 12 6 685-694 Pharmacoeconomic Methods, HTA Peer-Reviewed Journal Article
1997 Trakas K, Addis A, Kruk D, Buczek Y, Iskedjian M, Einarson TR. Quality assessment of pharmacoeconomic abstracts of original research articles in selected journals. Annals of Pharmacotherapy 31 4 423-428 Pharmacoeconomic Methods Peer-Reviewed Journal Article
1997 Agro K, Mittmann N, Bradley CA, Iskedjian M, Ilersich AL, Einarson TR. Sensitivity analysis in pharmacoeconomic studies: A literature analysis. PharmacoEconomics 11 1 75-88 Pharmacoeconomic Methods Peer-Reviewed Journal Article
1997 Addis A, Iskedjian M, Mittmann N, Einarson TR. Meta-analysis of the treatment of major depressive disorders. Canadian Journal of Clinical Pharmacology 4 1 43 CNS/Psychiatry Abstract
1997 Addis A, Iskedjian M, Mittmann N, Einarson TR. Meta-analysis of venlafaxine in the treatment of major depressive disorders. Pharmacoepidemiology and Drug Safety 6 Supp 2 S45 CNS/Psychiatry Abstract
1997 Einarson TR, Addis A, Iskedjian M, Mittmann N, Shane L. Pharmacoeconomic analysis of venlafaxine in depression. Canadian Journal of Clinical Pharmacology 4 1 46 CNS/Psychiatry Abstract
1997 Einarson TR, Addis A, Iskedjian M, Shane L. Pharmacoeconomic analysis of venlafaxine in depression. American Journal of Managed Care 3 3 S52 CNS/Psychiatry Abstract
1997 Einarson TR, Addis A, Iskedjian M, Mittmann N, Shane L. Pharmacoeconomic analysis of venlafaxine in depression. Pharmacoepidemiology and Drug Safety 6 Supp 2 S44 CNS/Psychiatry Abstract
1997 Iskedjian M, Addis A, Bradley-Kennedy C, et al. Quality assessment of economic evaluations published in PharmacoEconomics, 1992-1995. American Journal of Managed Care 3 3 S66 Pharmacoeconomic Methods, HTA Abstract
1997 Iskedjian M, Einarson TR. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: Results of a meta-analysis. Pharmacoepidemiology and Drug Safety 6 Supp 2 S44 Cardiovascular, Adherence, Compliance Abstract
1997 Iskedjian M, Gordon J. Cost-effectiveness analysis in health care: roles and limitations. Innovus Research Inc., Burlington, ON, Canada, March 1997 NA NA NA Pharmacoeconomic Methods, HTA Conference Presentations and Lectures
1997 Addis A, Iskedjian M, Mittmann N, Einarson TR. Meta-analysis of the treatment of major depressive disorders. Canadian Pharmacoepidemiology Forum, Hamilton, ON, Canada, April 1997 NA NA NA CNS/Psychiatry Conference Presentations and Lectures
1997 Addis A, Iskedjian M, Mittmann N, Einarson TR. Meta-analysis of venlafaxine in the treatment of major depressive disorders. 13th International Conference on Pharmacoepidemiology, Orlando, FL, August 1997 NA NA NA CNS/Psychiatry Conference Presentations and Lectures
1997 Einarson TR, Addis A, Iskedjian M, Mittmann N, Shane L. Pharmacoeconomic analysis of venlafaxine in depression. Canadian Pharmacoepidemiology Forum, Hamilton, ON, Canada, April 1997 NA NA NA CNS/Psychiatry Conference Presentations and Lectures
1997 Einarson TR, Addis A, Iskedjian M, Shane L. Pharmacoeconomic analysis of venlafaxine in depression. ISPOR 2nd Annual International Meeting, Philadelphia, PA, April 1997 NA NA NA CNS/Psychiatry Conference Presentations and Lectures
1997 Einarson TR, Addis A, Iskedjian M, Mittmann N, Shane L. Pharmacoeconomic analysis of venlafaxine in depression. 13th International Conference on Pharmacoepidemiology, Orlando, FL, August 1997 NA NA NA CNS/Psychiatry Conference Presentations and Lectures
1997 Iskedjian M, Addis A, Bradley-Kennedy C, et al. Quality Assessment of economic evaluations published in PharmacoEconomics, 1992-1995. ISPOR 2nd Annual International Meeting, Philadelphia, PA, April 1997 NA NA NA Pharmacoeconomic Methods, HTA Conference Presentations and Lectures
1997 Iskedjian M, Einarson TR. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: Results of a meta-analysis. 13th International Conference on Pharmacoepidemiology, Orlando, FL, August 1997 NA NA NA Cardiovascular, Adherence, Compliance Conference Presentations and Lectures
1996 Oh P, Einarson TR, Iskedjian M, Addis A, Lanctôt K. Pharmacoeconomic evaluation of risperidone and clozapine in chronic and treatment-resistant schizophrenia. Canadian Coordinating Office for Health Technology Assessment (CCOHTA), Ottawa NA NA NA CNS/Psychiatry Peer-Reviewed Report
1996 Addis A, Mittmann N, Iskedjian M, Einarson TR. Drug-related mortality in children in Canada (1984-1994). Pharmacoepidemiology and Drug Safety 5 Suppl 1 S21 Prescription Drug-Related Mortality, Pharmacoepidemiology Abstract
1996 Miller B, Blatman B, Einarson TR. A survey of population-based drug databases in Canada. Canadian Medical Association Journal 154 12 1855-1864 Pharmacovigilance, Pharmacoepidemiology Acknowledgement
1996 Iskedjian M. Cost-effectiveness analysis in health care: satisfying the client without compromising principles and guidelines. Graduate Department of Health Administration, Faculty of Medicine, University of Toronto, Toronto, ON, November 1996 NA NA NA Pharmacoeconomic Methods, HTA Conference Presentations and Lectures
1996 Addis A, Mittmann N, Iskedjian M, Einarson TR. Drug-related mortality in children in Canada (1984-1994). 11th International Conferences on Pharmacoepidemiology, Amsterdam, August 1996 NA NA NA Prescription Drug-Related Mortality, Pharmacoepidemiology Conference Presentations and Lectures
1996 Iskedjian M, Addis A, Einarson TR. Hospital admissions due to nonadherence to drug therapy: a meta-analysis. EURO DRUG 1st Meeting, Budapest-Aliga, Hungary, June 1996 NA NA NA Adherence, Compliance Conference Presentations and Lectures
1996 Iskedjian M, Addis A, Einarson TR. Hospital admissions due to nonadherence to drug therapy: meta-analysis and estimation of the economic impact in Canada. European Workshop on Drug Compliance Issues in Clinical Trials and Patient Care. The Drug Information Association, Paris, France, October 1996 NA NA NA Adherence, Compliance Conference Presentations and Lectures
1996 Iskedjian M, Einarson TR. The relationship between daily dose frequency and adherence to antihypertensive drug therapy: preliminary results of a meta-analysis. European Workshop on Drug Compliance Issues in Clniical Trials and Patient Care. The Drug Information Association, Paris, France, October 1996 NA NA NA Adherence, Compliance Conference Presentations and Lectures
1995 Bradley CA, Iskedjian M, Lanctôt K, et al. Quality assessment of economic evaluations in selected pharmacy, medical and health economics journals. Annals of Pharmacotherapy 29 7 681-689 Pharmacoeconomic Methods, HTA Peer-Reviewed Journal Article
1995 Iskedjian M, Janacek E, Einarson TR. Epidemiology of drug information requests at the Addiction Research Foundation, Toronto, Canada, 1982-1994. 11th International Conference on Pharmacoepidemiology, Montreal, QC, Canada, August 1995 NA NA NA Substance Abuse Conference Presentations and Lectures
1993 Iskedjian M. Copayment in drug benefit programs: a Canadian overview. Graduate Department of Health Administration, Faculty of Medicine, University of Toronto, Toronto, ON, December 1993 NA NA NA Pharmacy Copayment, Reimbursement Conference Presentations and Lectures
1993 Iskedjian M. Implementation of a pharmaceutical care service by a community pharmacist in Hamilton, Ontario: a marketing analysis. Graduate Department of Health Administration, Faculty of Medicine, University of Toronto, Toronto, ON, Canada, December 1993 NA NA NA Adherence, Compliance Conference Presentations and Lectures
CANADA

4 Macassa Circle
Kanata (Ottawa), ON
K2T 1J7
CANADA 

USA

1967 Wehrle Drive, Suite 9
Williamsville, NY
14221
USA 

E-mail:

ideas@pharmideas.com

Phone:

+1‍-613-614-4915

© Copyright 2020 PharmIdeas Research and Consulting Inc.- All Rights Reserved